Research with a destination | A question to investigate
Give a promising finding a useful next destination.
A research result and a commercial proposition answer different questions. Our interest is in the work between them: identifying who could use a finding, what they would need to trust it and which experiment should come next.
Start before the pitch becomes fixed.
An academic group may have a mechanism, a method, a material or a dataset with several possible applications. Choosing the most impressive story too early can conceal the most useful one. We propose a translation partnership that begins with the finding's actual strengths and limitations, then explores a small number of credible uses. The aim is to discover a decision worth supporting, not retrofit a customer narrative around every laboratory observation.
Find the user and the decision separately.
The person excited by a technology may not be the person who adopts it, pays for it or carries its risk. A proposed application should identify each of those roles. For medicines intelligence, that could mean separating a professional reviewer from an operational sponsor and a budget holder. For a laboratory method, it could mean distinguishing the scientist running an assay from the organisation deciding whether to change its workflow.
Establish what the research has actually shown.
The initial inputs would include the available evidence, experimental conditions, repeatability, known failure modes and rights to the relevant materials. We would map the distance between an observed result and the intended application. A method that performs well under one set of conditions may still need substantial work elsewhere. The useful question is what additional evidence would alter a prospective user's decision, rather than how many features could be added.
Compare with the option people already have.
A credible translation study needs a practical comparator: an established assay, an existing review process, a current supplier or the decision to do nothing. The comparison would include training, access, time and uncertainty as well as technical performance. An application can be scientifically interesting yet commercially unattractive if its advantage is too small or too difficult to realise. Learning that early protects the next research budget.
A public decision brief | An illustrative example
Open the question.
Inspect the reasoning.
Choose a business question, then look beneath its claim. See what a public source supports, what depends on the local setting and what a useful next step could be.
An academic or development team examining the next experiment after a published model comparison.
What does this result allow us to ask next?
A promising figure can sharpen a research question. Its value depends on keeping the model, observation and next hypothesis distinct.
A proposition to investigate
A clearer question can be a useful output.
An evidence brief could help a team distinguish a published observation from the experiment needed to investigate translation. The proposed value is a more precise comparison and an explicit evidence gap. It does not turn an external model result into a clinical claim or a NEUVIOR discovery.
This is a constructed research-planning question, not an agreed study or product-development result.
What the next brief would contain
A decision someone
can commission.
- The decision
- Whether a specific follow-on question has a credible experimental comparison.
- The comparator
- A scientifically justified model or condition relevant to the proposed hypothesis.
- The evidence
- Full methods, model relevance, measurements, replication and a feasible authorised protocol.
- Stop or redesign
- Stop or redesign if the proposed model cannot answer the question or the required work is not feasible.
Constructed public example | Not PHARMORIS-generated software output or a measured customer result.
Keep this example briefAgree the collaboration before creating new value.
The Intellectual Property Office's Lambert Toolkit provides starting points for university–business discussions, with its stated jurisdiction and currency limits (Intellectual Property Office, n.d.). It is not a substitute for a project-specific agreement. Background knowledge, newly generated results, publication, confidentiality and future exploitation would need clear terms. A university's participation would not itself transfer rights or establish NEUVIOR ownership of an invention, and a conversation would not become a claimed partnership.
Design a translation experiment that can disappoint.
Our proposed output is a short application dossier and a bounded experimental or user-research plan. An academic collaborator would help identify the scientific test; a prospective user would define the decision threshold. NIHR's i4i programme illustrates the importance of a credible adoption pathway for relevant technologies, without implying eligibility or funding for this proposal (NIHR, n.d.). The work should preserve alternatives and record why one application was selected over another.
Choose a next step with a real consequence.
The first discussion should bring one finding, one plausible application and the person responsible for its next decision. We would agree the smallest study that could justify further development, a change of direction or a stop. Continuation would require both a credible evidence path and a recognisable user need. If the rights are unresolved, the comparator is already sufficient or the proposed advantage cannot be tested economically, the responsible outcome is to pause.
The dossier should make the next meeting easier: a scientist can see the unresolved mechanism, an operator can see the practical constraint and a potential funder can see what the next experiment would decide. Different applications may require different partners, so keeping those routes visible can prevent an early exclusive story from closing a stronger opportunity.
Sources and context
NIHR (n.d.) Invention for Innovation. Available at: https://www.nihr.ac.uk/funding-programmes/invention-for-innovation (Accessed: 14 October 2026).
Intellectual Property Office (n.d.) Lambert collaboration toolkit. Available at: https://www.gov.uk/guidance/university-and-business-collaboration-agreements-lambert-toolkit (Accessed: 14 October 2026).
Another useful angle.
- Cell states and treatment resistance
Explore model-specific questions about changing cell states and treatment resistance, with credible controls, responsible methods and a bounded research proposal.
- Formulation feasibility research
Explore early formulation questions around stability, measurement and reproducibility, with a defined comparator and evidence needed for a development decision.
- Research design for smaller businesses
Frame a focused research question for a medicines SME, compare realistic alternatives and identify the smallest experiment that could change its next decision.
